ABSTRACT
Objective: To probe into the efficacy of Yishen Huashi granules combined with linagliptin tablets in the treatment of type 2 diabetic nephropathy (DN) and its effect on blood glucose and renal function in patients. Methods: 70 patients with type 2 DN at our hospital between May 2020 and May 2022 were chosen as the research objects and separated into the control group and the research group based on their treatments. With 35 cases in each group, the patients treated with initial therapy and linagliptin tablets were enrolled in the control group, and those who received the above treatments and also Yishen Huashi granules were included in the research group. Their clinical indexes such as blood glucose and renal function were compared with both groups after treatment. Results: After treatment, the research group had remarkably lower fasting blood glucose (FPG), 2 h-postprandial blood glucose (2 h-PBG), and glycosylated hemoglobin A1c (HbA1c) levels than those in the control group (P < 0.05). After treatment, the research group had remarkably lower levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein (LDL) (P < 0.05) and higher high-density lipoprotein (HDL) levels (P < 0.05) than those in the control group. After treatment, the urinary microalbumin (u-mALB) level was remarkably lower in both groups (P < 0.05) and was distinctly lower in the research group than in the control group (P < 0.05). After treatment, the research group had remarkably lower renal function indexes such as serum creatinine (SCr), blood urea nitrogen (BUN), urinary protein (UPro), and urinary albumin excretion rate (UAER) (P < 0.05) and a higher estimated glomerular filtration rate (eGFR) level (P < 0.05) than those in the control group. The efficacy was evaluated by the traditional Chinese medicine (TCM) syndrome score after treatment. There were no patients in complete remission between both the groups, where slight differences were found in the proportion of significant remission (P > 0.05), with the total effective rate of the research group remarkably higher than that of the control group (P < 0.05). Conclusion: The combination of Yishen Huashi granules and linagliptin tablets can reduce the blood glucose and blood lipid levels in patients with type 2 DN and lower UPro and protect renal function at the same time, which provides a new idea and a method for clinical treatment of type 2 DN with integrated traditional Chinese and Western medicine.
Subject(s)
Diabetes Mellitus, Type 2 , Diabetic Nephropathies , Albumins/therapeutic use , Blood Glucose , Cholesterol/therapeutic use , Creatinine/therapeutic use , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetic Nephropathies/drug therapy , Drugs, Chinese Herbal , Glycated Hemoglobin/analysis , Glycated Hemoglobin/therapeutic use , Humans , Kidney/chemistry , Kidney/physiology , Linagliptin/therapeutic use , Lipoproteins, HDL/therapeutic use , Lipoproteins, LDL/therapeutic use , Tablets/therapeutic use , Triglycerides/therapeutic useABSTRACT
Diabetes mellitus is a typical life threatening of disease, which generate due to the dysfunction of ß cells of pancreas. In 2014, WHO stated that 422â million people were infected with DM. The current pattern of management of diabetes included synthetic or plant based oral hypoglycemic drugs and insulin but drug resentence is become a very big issues in antidiabetic therapy. Thus, it's very earnest to discover now medication for this disease. Now the days, it is well acknowledged that diabetic patients are more prone towards covid and related complications. Thus, medical practitioners reformed the methodology of prescribing medication for covid infected antidiabetic therapy and encouraging the medication contains dual pharmacological properties. It is also well know that polyphenols specifically hold a significant role in oxidative stress and reduced the severity of many inflammatory diseases. Cucumis melo has rich history as ethano-pharmacological use in Indian subcontinent. The fruit and seed are well-known for the treatment of various diseases due to the presence of phenolics. Therefore, in this study, the combined mixture of flower and seeds were used for the extraction of polyphenolic rich extract and tested for antidiabetic activity through the antioxidant and inâ vivo experiments. The antioxidant potential measurement exhibited that the selected plant extract has the significant competence to down-regulate oxidative stress (DPPH scavenging IC50 at 60.7±1.05â µg/mL, ABTS IC50 at 62.15±0.50â µg/mL). Furthermore, the major polyphenolic phyto-compounds derived from the Cucumis melo were used for inâ silico anticovid activity, docking, and complementarity studies. The anticovid activity prognosis reflected that selected phyto-compounds amentoflavone and vanillic acid have optimal possibility to interact with 3C-like protease and through this moderate anticovid activity can be exhibit. The docking experiments established that the selected compounds have propensity to interact with protein tyrosine phosphatase 1B, 11ß-Hydroxysteroid dehydrogenase, superoxide dismutase, glutathione peroxidase, and catalase ß-glucuronidase receptor. Inâ vivo experiments showed that 500â mg/kg, Cucumis melo extract ominously amplified body weight, plasma insulin, high-density lipoprotein levels, and biochemical markers. Furthermore, extract significantly downregulate the blood glucose, total cholesterol, triglycerides, low-density lipoprotein, and very low-density lipoprotein.
Subject(s)
COVID-19 , Cucumis melo , Diabetes Mellitus, Experimental , Momordica , 11-beta-Hydroxysteroid Dehydrogenases , Animals , Antioxidants/pharmacology , Antioxidants/therapeutic use , Biomarkers , Blood Glucose , Catalase/metabolism , Cholesterol , Cucumis melo/metabolism , Diabetes Mellitus, Experimental/metabolism , Glucuronidase , Glutathione Peroxidase/metabolism , Humans , Hypoglycemic Agents/pharmacology , Hypoglycemic Agents/therapeutic use , Insulin , Lipoproteins, HDL/therapeutic use , Lipoproteins, LDL/therapeutic use , Momordica/metabolism , Peptide Hydrolases , Plant Extracts/chemistry , Protein Tyrosine Phosphatase, Non-Receptor Type 1 , Superoxide Dismutase/metabolism , Triglycerides , Vanillic AcidABSTRACT
Acacia jacquemontii possess has numerous traditional therapeutic uses. The rationale of this study was to investigate the role of Acacia jacquemontii ethyl acetate extract (AJEAE) in the downregulation of hyperglycemia. The current study was performed in two parts, in vitro, through characterization (high-performance liquid chromatography), estimation of total phenolic content, total flavonoid content, antioxidant (2,2-diphenyl-1-picrylhydrazylassay), and α-amylase inhibitory activities of the studied extract, and in vivo using Wistar rats in which animals were divided into five groups NC, DC, GL, AJEAE 250 mg/kg, and AJEAE 500 mg/kg. The effects of AJEAE on fasting plasma glucose, plasma insulin, HOMA-IR, oral glucose tolerance test, glycated hemoglobin (HBA1c), lipid profile, inflammatory cytokines (Interleukin-6, tumor necrosis factor-alpha), and oxidative stress markers (lipid peroxidation, nitic oxide, superoxide dismutase, catalase, glutathione peroxidase) were evaluated. Our findings confirmed the presence of quercetin, kaempferol, gallic acid, vanillic acid, syringic acid, M-coumaric acid, sinapic acid, chlorogenic acid, cinnamic acid, and ferulic acid in AJEAE. Total flavonoid and phenolic contents in AJEAE were 83.83 mg GAE/g and 77.06 mg QE/g, respectively. Significant inhibition of DPPH (69.470%/1 mg/ml) and α-amylase (71.8%/1 mg/ml) activities were exhibited by AJEAE. Alloxan-injected rats showed marked hyperglycemia and hypoinsulinemia, and increased inflammatory marker levels as compared to normal control (p < 0.001). Additionally, raised levels of triglyceride (139.7 ± 2.771), total cholesterol (198.7 ± 1.856), very low-density lipoprotein (33.43 ± 0.2728), low-density lipoprotein (155.5 ± 2.754), lipid peroxidation, and nitric oxide (p < 0.001) and decreased levels of high-density lipoprotein (17.20 ± 0.1732), superoxide dismutase, catalase, and glutathione peroxidase were observed in diabetic rats (p < 0.001). AJEAE significantly (p < 0.05) improved the aforementioned parameters and the protective efficacy was comparable to glibenclamide. Histopathological findings also evidenced the anti-hyperglycemic properties of AJEAE through regeneration of pancreatic ß cells. Conclusively, our findings demonstrated the antihyperglycemic, antihyperlipidemic, antioxidant, anti-inflammatory, and pancreatic beta ß cell regenerative properties of AJEAE against alloxan-induced diabetes.
Subject(s)
Acacia , Diabetes Mellitus, Experimental , Hyperglycemia , Plant Extracts , Acacia/chemistry , Alloxan , Animals , Antioxidants/metabolism , Blood Glucose , Catalase , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/drug therapy , Flavonoids , Glutathione Peroxidase , Hyperglycemia/chemically induced , Hyperglycemia/drug therapy , Lipoproteins, LDL/therapeutic use , Lipoproteins, LDL/toxicity , Oxidative Stress , Plant Extracts/chemistry , Plant Extracts/pharmacology , Rats , Rats, Wistar , Superoxide Dismutase , alpha-AmylasesABSTRACT
Background: Green tea, obtained from the plant Camellis sinensis, is one of the oldest drinks in the world and contains numerous bioactive compounds. Studies have demonstrated the efficacy of green tea in preventing obesity and cardiovascular diseases that may be related to the reduction of lipid levels. Aim: This study aimed to evidence, through a systematic review, the therapeutic potential of green tea on the lipid profile in preclinical studies in obese animals and clinical studies in obese individuals. Methods: This systematic review follows the recommendations of the preferred report items for systematic reviews and meta-analyses. The electronic databases, PubMed (Medline), Science Direct, Scopus, and Web of Science were consulted. Articles from January 2009 to December 2019 were selected. Results: This search resulted in twenty-nine articles were included cirtically reviewed. In experimental studies, green tea administration has been shown to reduce total cholesterol, triglycerides and low-density lipoprotein cholesterol in animals exposed to obesity-inducing diet. In humans' studies green tea was not shown to be effective for obese lipid control. Because supplementation with green tea extract reduced total cholesterol, triglycerides, low-density lipoprotein for three months at a specific dose. Conclusion: Therefore, green tea appears to act as a protective agent for dyslipidemia in obesity-induced animals. In human studies, green tea has not been shown to be effective in controlling obese lipids.
Subject(s)
Obesity , Tea , Animals , Cholesterol , Humans , Lipoproteins, LDL/therapeutic use , Obesity/drug therapy , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , TriglyceridesABSTRACT
Two flavonoids, gnaphaliin and tiliroside, isolated from Helichrysum italicum, were studied in vitro for their capacity to inhibit Cu(2+)-induced human low density lipoprotein (LDL) and diluted plasma oxidation. LDL oxidation was monitored by conjugated diene, thiobarbituric acid-reactive substances (TBARS) formation and electrophoretic mobility on agarose gel. Gnaphaliin and tiliroside increased the lag-phase for diene conjugate production in a dose-dependent manner. The reduction of TBARS production confirmed the antioxidant activity of gnaphaliin and tiliroside with 50% inhibitory concentration (IC(50)) values of 8.0+/-3.9 microM and 7.0+/-2.6 microM respectively. Furthermore, the flavonoids negated the Cu(2+)-induced increase in electrophoretic mobility of LDL. Antioxidant activity of gnaphaliin and tiliroside was significantly different when diluted plasma was oxidised by adding 1 mM CuSO(4). Although both flavonoids again reduced the TBARS production, tiliroside showed higher activity than gnaphaliin (IC(50)=10.6+/-2.5 microM vs. IC(50)>50 microM). In conclusion, tiliroside and gnaphaliin are antioxidants against in vitro Cu(2+)-induced LDL oxidation in the same order of magnitude compared to that of the reference drug, probucol.
Subject(s)
Benzopyrans/pharmacology , Cholesterol, LDL/drug effects , Flavones/pharmacology , Helichrysum , Lipid Peroxidation/drug effects , Lipoproteins, LDL/pharmacology , Phytotherapy , Benzopyrans/administration & dosage , Benzopyrans/therapeutic use , Copper Sulfate/chemistry , Flavones/administration & dosage , Flavones/therapeutic use , Flavonoids , Humans , Inhibitory Concentration 50 , Lipoproteins, LDL/administration & dosage , Lipoproteins, LDL/therapeutic use , Plant Components, Aerial , Plant Extracts/administration & dosage , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Thiobarbituric Acid Reactive Substances/chemistryABSTRACT
Objetivo: Revisar los efectos de la terapia hormonal sustitutiva, en sus distintas formas, en el metabolismo lipídico.Fuentes: Bibliografía médica hasta septiembre del año 2000 a través de MEDLINE.Conclusiones: Los estrógenos, combinados o no con progestágenos, inducen un perfil lipoproteico favorable. Buena parte de esa acción se ejerce a través de modificación en la cinética de partículas.Las acciones sobre oxidación de las lipoproteínas de baja densidad (LDL), o el tamaño de sus partículas, son motivo de polémica. Nuevos preparados, con capacidad de activar receptores estrogénicos, también demuestran ejercer acciones selectivas sobre el metabolismo lipídico. Objetivo: Revisar los efectos de la terapia hormonal sustitutiva, en sus distintas formas, en el metabolismo lipídico.Fuentes: Bibliografía médica hasta septiembre del año 2000 a través de MEDLINE.Conclusiones: Los estrógenos, combinados o no con progestágenos, inducen un perfil lipoproteico favorable. Buena parte de esa acción se ejerce a través de modificación en la cinética de partículas.Las acciones sobre oxidación de las lipoproteínas de baja densidad (LDL), o el tamaño de sus partículas, son motivo de polémica. Nuevos preparados, con capacidad de activar receptores estrogénicos, también demuestran ejercer acciones selectivas sobre el metabolismo lipídico (AU)